Paul Kim

Paul Kim

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2018 in Minerals
Verified
Journal Article
Open access
PDF file
PKPaul Kim
Paul Kim
Andrzej AnderkoAndrzej Anderko
Andrzej Anderko
ANAlexandra Navrotsky
Alexandra Navrotsky
RRRichard Riman
Richard Riman
A general overview of the trends in structural and thermodynamic properties that have been identified within the hydrated normal rare earth carbonates and the rare earth hydroxycarbonates is presented. Based upon available literature, we demonstrate the trends in crystallographic unit cell parameters, thermal stability, aqueous solubility, and thermochemical properties. These trends can be attributed to both the unique chemistry and strong similarity of the rare earth elements. There are also inconsistent trends that signal research needs to better understand the structure–energy relationships of the rare earth carbonates.

12 February 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
PKPaul Kim
Paul Kim
CLCheng Li
Cheng Li
RRRichard Riman
Richard Riman
JWJames J. Watkins
James J. Watkins

1 July 2009 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
ESEugene P. Snissarenko
Eugene P. Snissarenko
GKGrace H. Kim
Grace H. Kim
ASAlfred A. Simental
Alfred A. Simental
JZJon E. Zwart
Jon E. Zwart
DRDarron M. Ransbarger
Darron M. Ransbarger
PKPaul Kim
Paul Kim

6 April 2022 in ACS Omega
Verified
Journal Article
Open access
MGMichael S. Guzman
Michael S. Guzman
JIJaisree Iyer
Jaisree Iyer
PKPaul Kim
Paul Kim
DKDaniel Kopp
Daniel Kopp
ZDZiye Dong
Ziye Dong
YJYongqin Jiao
Yongqin Jiao
Biocement formed through microbially induced calcium carbonate precipitation (MICP) is an emerging biotechnology focused on reducing the environmental impact of concrete production. In this system, CO2 species are provided via ureolysis by Sporosarcina pasteurii (S. pasteurii) to carbonate monocalcium silicate for MICP. This is one of the first studies of its kind that uses a solid-state calcium source, while prior work has used highly soluble forms. Our study focuses on microbial physiological, chemical thermodynamic, and kinetic studies of MICP. Monocalcium silicate incongruently dissolves to form soluble calcium, which must be coupled with CO2 release to form calcium carbonate. Chemical kinetic modeling shows that calcium solubility is the rate-limiting step, but the addition of organic acids significantly increases the solubility, enabling extensive carbonation to proceed up to 37 mol %. The microbial urease activity by S. pasteurii is active up to pH 11, 70 °C, and 1 mol L–1 CaCl2, producing calcite as a means of solidification. Cell-free extracts are also effective albeit less robust at extreme pH, producing calcite with different physical properties. Together, these data help determine the chemical, biological, and thermodynamic parameters critical for scaling microbial carbonation of monocalcium silicate to high-density cement and concrete.

25 June 2020 in Journal of Materials Engineering and Performance
Verified
Journal Article
Closed access
PDF file
PKPaul Kim
Paul Kim
GDGaurav Das
Gaurav Das
MLMalgorzata M. Lencka
Malgorzata M. Lencka
AAAndre Anderko
Andre Anderko
RRRichard E. Riman
Richard E. Riman

25 March 2023 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
PKPaul Kim
Paul Kim
RRRamin Raiszadeh
Ramin Raiszadeh
DBDavid A. Bomback
David A. Bomback
DKDavid L. Kramer
David L. Kramer
MMMichael Moghimi
Michael Moghimi
Background: To investigate the clinical safety and efficacy of ViBone® Viable Bone Matrix (VBM), a next generation cellular bone matrix allograft that comprises all three essential bone-forming components: osteogenic, osteoinductive, and osteoconductive factors, and is optimized to enhance cell viability and bone formation. Methods: This was a multi-center, prospective, post-market study evaluating the safety and efficacy of ViBone VBM in patients undergoing 1–3 level anterior cervical discectomy and fusion or lumbar interbody fusion surgery. Patients were evaluated at baseline, 6-month, and 12-month follow-up clinically and radiographically. Clinical assessment included Visual Analog Scale for pain (VAS-pain), the Neck Disability Index (NDI) for patients with cervical pathologies, and the Oswestry Disability Index (ODI) for patients with lumbar pathologies. Fusion success defined by an independent radiologist was determined radiographically by plain films. Results: Clinical outcomes evaluated with VAS-pain, NDI, and ODI scales were improved significantly at 6 and 12 months compared to baseline. All patients reached clinically significant improvements at 12 months. There were no adverse events or infections attributed to ViBone VBM. At 12 months, the fusion rate per patient was 88.1% in cervical and 97.6% in lumbar patients, while per-level fusion was 98.5% for cervical and 100% for lumbar segments. Conclusions: Patients undergoing cervical and lumbar spinal fusion implanted with ViBone VBM demonstrated favorable outcomes at 6 months and 12 months as measured by subjective clinical measures and radiographic fusion rates. Trial registration This study was registered as NCT03425682 on 1/29/2018.